On June 9, 2021, Nautilus Biotechnology, a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the completion of its business combination with Arya Sciences Acquisition Corp III, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. The combined company, Nautilus Biotechnology, began trading shares of its common stock under the ticker symbol "NAUT" on the Nasdaq Global Select Market on June 10, 2021. The business combination was approved by Arya III’s shareholders on June 8, 2021. Gross proceeds from this transaction totaled approximately $345 million, which included approximately $145 million of funds held in Arya III’s trust account and the concurrent common stock private investment in public equity (PIPE) financing of $200 million led by Perceptive Advisors, an affiliate of Arya III’s sponsor, as well as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., Casdin Capital, and existing Nautilus Biotechnology shareholders including Andreessen Horowitz, Madrona Venture Group, and Vulcan Capital.

Wilson Sonsini Goodrich & Rosati represented Nautilus Biotechnology in the transaction. The team includes:

Corporate
Rob Kornegay, Partner
Michael Nordtvedt, Partner
Zachary Myers, Partner
Benjamin Capps, Associate
Bridget Balisy, Associate

M&A
Robert Ishii, Partner
Brian Keyes, Partner
Ross Tanaka, Associate

Employee Benefits and Compensation
Scott McCall, Partner
Jaqueline Tokuda, Partner

Tax
Jonathan Zhu, Partner
Derek Wallace, Partner
Joe Mandry, Associate

Delaware Law
Amy Simmerman, Partner
Ryan Greecher, Partner

IP – Patents and Innovations
Vern Norviel, Partner
Rona Lamiquiz, Associate

For more information, please see Nautilus Biotechnology's press release.